Armed with Pfizer's ADC platform, Pyxis scores $152M round to shoot for the clinic while taking its time on I/O programs
Lara Sullivan knows how empowering it can be for a biotech to bring in experimental drugs from Pfizer’s shelves. An alum of the pharma giant …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
